Merus (MRUS) Stock Price, News & Analysis

Company Overview

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Key Stats

• Today's Range: $66.17 to $69.20
• 50-Day Range: $52.33 to $67.49
• 52-Week Range: $33.19 to $69.20
• Volume: 888,805 shs
• Average Volume: 860,870 shs
• Market Capitalization: $5.03 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $88.75
• Consensus Rating: Buy

Merus Stock Analysis - MarketRank™

Merus scored higher than 47% of companies evaluated by MarketBeat, and ranked 622nd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Merus has received a consensus rating of Buy. The company's average rating score is 3.08, and is based on 11 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Merus has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Merus are expected to decrease in the coming year, from ($3.85) to ($4.17) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Merus is -12.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Merus is -12.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Merus has a P/B Ratio of 6.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.44% of the float of Merus has been sold short.

Short Interest Ratio / Days to Cover

Merus has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in Merus has recently increased by 3.30%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Merus does not currently pay a dividend.

Dividend Growth

Merus does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.44% of the float of Merus has been sold short.

Short Interest Ratio / Days to Cover

Merus has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in Merus has recently increased by 3.30%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.17

News Sentiment

Merus has a news sentiment score of 1.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Merus this week, compared to 7 articles on an average week.

Search Interest

4 people have searched for MRUS on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Merus to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Merus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,586,340.00 in company stock.

Percentage Held by Insiders

Only 3.70% of the stock of Merus is held by insiders.

Percentage Held by Institutions

96.14% of the stock of Merus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MRUS Stock Analysis - Frequently Asked Questions

How have MRUS shares performed this year?

Merus' stock was trading at $42.05 at the start of the year. Since then, MRUS stock has increased by 61.5% and is now trading at $67.9070.

How were Merus' earnings last quarter?

Merus N.V. (NASDAQ:MRUS) issued its quarterly earnings data on Tuesday, August, 5th. The biotechnology company reported ($2.23) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by $1.06. The biotechnology company had revenue of $8.83 million for the quarter, compared to analysts' expectations of $9.77 million. Merus had a negative trailing twelve-month return on equity of 50.28% and a negative net margin of 685.64%.

When did Merus IPO?

Merus (MRUS) raised $64 million in an initial public offering on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

Who are Merus' major shareholders?

Top institutional investors of Merus include Commodore Capital LP (4.66%), Holocene Advisors LP (2.94%), Westfield Capital Management Co. LP (2.70%) and Franklin Resources Inc. (2.43%). Insiders that own company stock include Sven Ante Lundberg, Harry Shuman and Peter B Silverman.
View institutional ownership trends.

How do I buy shares of Merus?

Shares of MRUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Merus own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Merus investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), e.l.f. Beauty (ELF), Adobe (ADBE), Jabil (JBL) and Disc Medicine (IRON).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 8/28/2025
• Next Earnings (Estimated): 10/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MRUS
• CIK: 1651311
• Web: www.merus.nl
• Phone: (130) 253-8800
• Fax: N/A
• Employees: 37
• Year Founded: 2003

Price Target and Rating

• Average Price Target for Merus: $88.75
• High Price Target: $110.00
• Low Price Target: $70.00
• Potential Upside/Downside: +31.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.08
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$215.33 million
• Net Margins: -685.64%
• Pretax Margin: -670.59%
• Return on Equity: -50.28%
• Return on Assets: -42.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.39
• Quick Ratio: 8.39

Sales & Book Value

• Annual Sales: $56.23 million
• Price / Sales: 90.50
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.13 per share
• Price / Book: 6.04

Miscellaneous

• Outstanding Shares: 75,634,000
• Free Float: 72,836,000
• Market Cap: $5.09 billion
• Optionable: Optionable
• Beta: 1.09